Development of new medications is a lengthy and costly process. Finding novel indications for existing drugs, or drug repositioning, can serve as a useful strategy to shorten the development cycle. In this study, we develop a general framework for drug discovery or repositioning by predicting indication for a particular disease based on expression profiles of the drugs. Drugs that are not originally indicated for the disease but with high predicted probabilities serve as good candidates for repurposing. This framework is widely applicable to any chemicals or drugs with expression profiles measured, even if the drug targets are unknown. The method is also highly flexible as virtually any supervised learning algorithms can be used.
INTRODUCTION
Development of new medications is a very lengthy and costly process. While investment in research and development has been increasing, there is a lack of proportional rise in the number of drugs approved in the past two decades, especially for drugs with novel mechanisms of actions 1 . There is an urgent need for innovative approaches to improve the productivity of drug development. This is particularly true for some areas like psychiatry, for which there has been lack of therapeutic advances for some time 2, 3 .
Finding new indications for existing drugs, an approach known as drug repositioning or repurposing, can serve as a useful strategy to shorten the development cycle 4 . Repurposed drugs can be brought to the market in a much shorter time-frame and at lower costs. With the exponential growth of "omics" and other biomedical data in recent years, computational drug repositioning provides a fast, cost-effective and systematic way to identify promising repositioning opportunities 4 .
In this study we develop a general drug repositioning framework by predicting drug indications based on their expression profiles, with a focus on applications in psychiatry. We treat drug repositioning as a supervised learning problem and apply different state-of-the-art machine learning methods for prediction. Drugs that are not originally indicated for the disease but have high predicted probabilities serve as good candidates for repositioning. There are several advantages of this approach. Firstly, the presented approach is a general and broad framework that leverages machine learning methodologies, a field with very rapid advances in the last decade. This provides great flexibility and opportunities for further improvement in the future as virtually any supervised learning methods can be applied. Newly developed prediction algorithms can be readily incorporated to improve the detection of useful drug candidates. In addition, the framework presented here is widely applicable to any chemical or drugs with expression profiles recorded, even if the drug targets or mechanisms of actions are unknown. For example, herbal medicine products may contain a mixture of ingredients with uncertain drug targets; even for many known medications (e.g. lithium 5 ), their mechanisms of actions and exact targets are not completely known. If transcriptomic profiling has been performed, they can still be analyzed for therapeutic or repositioning potential under the current framework.
There has been increasing interest in computational drug repositioning recently, in view of the rising cost of new drug development. Hodos et al. 6 provided a comprehensive and updated review on this topic. Similarity-based methods (e.g. [7] [8] [9] [10] [11] [12] ) represent one common approach, but as noted by Hodos et al., the dependence on data in the "nearby pharmacological space" might limit the ability to find medications with novel mechanisms of actions 6 . Another related methodology is the network-based approach 13 , which typically requires data on the relationship between drugs, genes and diseases as well as connections within each category (e.g. drug-drug similarities). It can integrate different sources of information but may still be constrained by the focus on a nearby pharmacological space and the choice of tuning parameters in network construction or inference is often ad hoc 6 . The present work is different in that we offer a broad framework for repositioning and we do not focus on one but many different kinds of learning methods. There is comparatively less reliance on known drug mechanisms or the "nearby pharmacological space" as we let the different algorithms "learn" the relationship between drugs, genes and disease in their own ways. For high-throughput omics data, often only a subset of genes or input features are relevant and a machine learning approach is able to "learn" which features to consider for repositioning. We are particularly interested in applying the framework to psychiatric disorders in view of the lack of novel treatments in the area and that focusing on a specific disease area enables more in-depth investigation of the individual repositioning results.
It is worth noting that while psychiatric disorders are leading causes of disability worldwide 14 , there have been limited advances in the development of new pharmacological agents in the last two decades or so 3 . Investment by drug companies has been declining, and new approaches for drug discoveries are very much needed in this field. We will explore repositioning opportunities for schizophrenia along with depression and anxiety disorders.
Three major contributions of this study are summarized below. Firstly, we presented a general machine learning framework for drug repositioning, leveraging drug expression profiles as predictors. Secondly, we performed a thorough comparison of the predictive performances of various state-of-the-art machine learning algorithms, including deep neural networks, support vector machines, elastic net, random forest and gradient boosted trees. Thirdly, we identified new repositioning opportunities for schizophrenia as well as depression and anxiety disorders, and validated the relevance of the repositioned drugs by showing their enrichment among drugs considered for clinical trials, as well as inspection of individual repositioning hits for literature support. We also found that methods with slightly lower predictive accuracy still reveal literature-supported repositioning candidates that are of different mechanisms of actions from the drugs listed by the best-performing algorithm.
METHODS
We present a general drug repositioning framework adopting a supervised learning approach. We construct prediction models in which the outcome is defined as whether the drug is a known treatment for the disease, and the predictors are expression profiles of each drug. Drugs that are not originally known to treat the disease but have high predicted probabilities are regarded as good candidates for repositioning.
Drug expression data
The expression data is downloaded from the Connectivity Map (CMap), which captures transcriptomic changes when thee cell lines (HL60, PC3, MCF7) were treated with a drug or chemical 15 . We downloaded raw expression data from Cmap, and performed normalization with the MAS5 algorithm 16 . Expression levels of genes represented on more than one probe sets were averaged. We employed the limma package 17 to perform analyses on differential expression between treated cell lines and controls. Analyses were performed on each combination of drug and cell line, with a total of 3478 instances. Expression measurements were available for 12436 genes. Statistical analyses were performed in R3.2.1 with the help of the R package "longevityTools".
Defining drug indications
Drug indications were extracted from two known resources, namely the Anatomical Therapeutic Chemical (ATC) classification system and the MEDication Indication Resource high precision subset (MEDI-HPS) 18 . We focus on schizophrenia as well as depression and anxiety disorders in this study. From the ATC classification system, two groups of drugs were extracted, including antipsychotics and antidepressants. On the other hand, the MEDI-HPS dataset integrates four public medication resources, including RxNorm, Side Effect Resource 2 (SIDER2) 19 , Wikipedia and MedlinePlus. We used the MEDI high-precision subset (MEDI-HPS) which only include drug indications found in RxNorm or in at least 2 out of 3 other sources 18 . This subset achieves a precision of up to 92% according to Wei et al. 18 .
Machine learning methods
We employed different state-of-the-art machine learning approaches including deep neural networks (DNN) 20 , support vector machine (SVM) 21 , random forest (RF) 22 , gradient boosted machine with trees (GBM) 23 and logistic regression with elastic net regularization (EN) 24 to predict indications.
DNN was implemented in the python package keras. In our deep learning model, hyperparameters were chosen by the "fmin" optimization algorithm from "hyperopt", which employs a sequential model-based optimization approach 25 . Fifty evaluations were run for each search of optimal hyper-parameters. Dropout and mixed L1/L2 penalties were employed to reduce over-fitting. The neural networks consisted of two or three layers, with number of nodes selected uniformly from the range [64, 1024]. Dropout percentage was selected uniformly from [0.25, 0.75], and L1/L2 penalty uniformly from [1E-5, 1E-3]. Optimizer was chosen from "adadelta" 26 , "adam" 27 and "rmsprop" 28 , and the activation function chosen from "relu", "softplus" or "tanh". One hundred epochs were run for each model and we extracted the model weights corresponding to the best epoch. SVM, RF and GBM models were implemented in "scikit-learn" (sklearn) in python. Hyper-parameter selection was performed by the built-in function GridSearchCV in sklearn. For SVM, we chose radial basis function as the kernel. The two hyper-parameters C and gamma were selected from {1, 10, 100, 1000} and {1E-3, 1E-4} respectively. For RF, the number of bagged trees was set to 1000 and the maximum number of features used for splitting was selected from {50, 100, 500, 1000, 3000, 5000}. For GBM, the number of boosting iterations was set to 100; learning rate was selected uniformly from [0.05, 0.2], subsampling proportion uniformly from [0.7, 1], max depth of splitting from {5, 6, 7, 8} and maximum number of features from {50, 100, 500, 1000, 3000, 5000}. A randomized search with 20 iterations was performed for GBM. Finally, the EN model was implemented by the R package "glmnet" 29 . The elastic-net penalty parameter α was chosen from seq(0, 1, by=0.1), with other settings following the default.
Nested Cross-validation
We adopted nested three-fold cross validation (CV) to choose hyper-parameters and evaluate model performances. It has been observed that optimistic bias will result if one uses simple CV to compute an error estimate for a prediction algorithm that itself is tuned using CV 30 . Nested CV avoids this problem and is able to give an almost unbiased estimate of prediction accuracy 30 . The inner loop CVs were used to choose the parameters that optimized predictive performance. In each outer loop CV we made predictions on the corresponding test set using the best model trained from the inner CV loops. To achieve maximum consistency in our comparisons, we compared different methods on the same test set in each loop. Note that the test sets were not involved in model training or parameter tuning.
Predictive performance measures
The performances of the machine learning methods were evaluated in the test sets using three metrics, including log loss, area under the receiver operating characteristic curve (ROC-AUC) and area under the precision recall curve (PR-AUC). Log loss compares the predicted probabilities against the true labels. The receiver operating characteristic curve, which plots the sensitivity (i.e. recall) against (1-specificity), is a widely used approach to evaluate predictive performances in medical applications. The precision-recall curve on the hand plots the precision (i.e. positive predictive value) against the sensitivity (recall). Since precision depends on the overall proportion of positive labels, the PR-AUC is also dependent on such proportions. Davies et al. 31 suggested that the PR curve may give more informative comparisons when working with imbalanced data, which is the case for our dataset.
External validation by testing for enrichment of psychiatric drugs considered for clinical trials
We then performed additional analyses to assess if the drugs with high predicted probabilities from our machine learning models are indeed good candidates for repositioning. Briefly, we tested whether the drugs with no known indication for the disease but high predicted probabilities are more likely to be included in clinical trials.
In the first step, we filtered off drugs that are known to be indicated for the disease as derived from ATC and MEDI-HPS. This is because we are mainly interested in repositioning other drugs of unknown therapeutic potential, and that the labels of drug indication (from ATC or MEDI-HPS) have already been utilized in the machine learning prediction steps. Next, we extracted a list of drugs that were included in clinical trials for schizophrenia as well as depression and anxiety disorders. The list was derived from clincialTrial.gov and we downloaded a pre-complied version from https://doi.org/10.15363/thinklab.d212.
We then tested for enrichment of those drugs listed in clinicalTrial.gov among the top repositioning results. We performed a "drug-set" enrichment analysis, similar to a gene-set analysis approach widely used in bioinformatics 32 . We performed one-tailed t-tests to assess if the predicted probabilities (derived from machine learning models) are significantly higher for psychiatric drugs considered in clinical trials.
RESULTS

Predictive performance comparison
The average predictive perfomances (averaged over three folds) of different machine learning methods are listed in Table 1 . When considering log loss as the criteria of interest, SVM gave the best result overall, though EN showed the best performance in one of the four datasets. DNN and EN showed quite similar prediction power, with EN having a slight advantage. RF and GBM achieved the poorest prediction accuracy, and RF performed worse within the two tree-based methods.
When ROC-AUC was considered as the performance metric, SVM and EN gave similar performances. SVM outperformed EN in the schizophrenia datasets, while EN showed better results in the other two datasets. The performance of DNN was worse than that of SVM and EN, although the differences were not large. The two tree-based methods had the lowest ROC-AUC, especially for RF.
We then considered PR-AUC, which is more sensitive to imbalanced data, as the measure of predictive performance. SVM had an obvious advantage over other models, dominating the other machine learning models in all datasets. EN and DNN followed with very similar performances. Consistent with other performance measures, GBM and RF had the worst performances, with GBM surpassing RF.
In summary, SVM had the best prediction accuracy overall, followed by EN and DNN. EN and DNN were close to each other, though EN appeared to perform better than DNN when ROC-AUC was considered. The prediction accuracy of the two tree-based methods was the worst, and RF had the worst prediction power among the five methods in all experimental datasets.
Enrichment for psychiatric drugs considered in clinical trials
We further tested whether the top repositioning results are enriched for psychiatric medications included in clinical trials. We did not include GBM and RF as their predictive performances were not as satisfactory as the other methods. As shown in Table 2 , when we considered the drugs that have been included in clinical trials of psychiatric disorders, we observed an enrichment of such drugs for both schizophrenia and depression and anxiety disorders in most cases. This provides further support to the validity of our approach in identifying new repositioning opportunities. Table 3 shows the top 15 repositioning hits by SVM for schizophrenia as well as depression and anxiety disorders. Note that drugs that are indicated for these disorders according to ATC or MEDI-HPS are excluded from the lists. Regarding depression and anxiety disorders, interestingly many of the top results are antipsychotics, such as trifluoperazine, perphenazine, fluphenazine and chlorpromazine, among others. Antipsychotics have long been used for the treatment for depression 33 . In earlier studies, phenothiazines (a class of antipsychotic to which many of the top repositioning hits belong) was observed to produce similar anti-depressive effects as tricyclic antidepressants 34 . Due to the risk of extra-pyramidal side-effects, typical antipsychotics are less commonly used these days and second-generation (atypical) antipsychotics are more often prescribed. Meta-analyses have shown that atypical antipsychotics are effective as adjunctive or primary treatment for depression 35, 36 . Antipsychotics are also commonly prescribed for severe depressive episodes with psychotic symptoms. A few other drugs on the list are also worth mentioning. Cyproheptadine is a 5-HT 2 receptor antagonist and was shown to improve depression in a small cross-over trial 37 . It was also reported that the drug reduced the neuropsychiatric side-effects of the antiviral therapy efavirenz, including depressive and anxiety symptoms 38 . Metergoline is a non-specific serotonin antagonist that has been shown to ameliorate depressive symptoms in seasonal affective disorder 39 . Chlorcyclizine belongs to the phenylpiperazine class and numerous antidepressants and antipsychotics also belong to this class 40 .
Top repositioning hits and literature support from previous studies
With regards to repositioning results for schizophrenia, some of the hits are antidepressants, such as protriptyline, maprotiline and clomipramine. Antidepressants are frequently prescribed in schizophrenia patients due to risks of comorbid depression or obsessive-compulsive disorder 41 . In meta-analyses antidepressants were also found to improve negative symptoms of schizophrenia 42, 43 . For the antidepressants on the list, maprotilinehas been reported to improve negative symptoms in chronic schizophrenia patients 44 as an adjunctive treatment and clomipramine has been shown to ameliorate not only obsessive-compulsive but also overall schizophrenic symptoms in patients with comorbid disorders 45 . Interestingly, the mood stabilizer valproate was also listed among the top. Valporate may improve clinical response when added to antipsychotics, although the evidence is mainly based on open randomized controlled trials (RCTs) 46 . Another drug nordihydroguaiaretic acid has antioxidant properties 47 and may be useful in combating oxidative stress in schizophrenia 48 . Aspirin, a non-steroidal anti-inflammatory agent on the list, has also been shown to improve schizophrenia symptoms 49 .
The top repositioning results of DNN and EN are listed in Table 4 -5. Notably, while there is partial overlap with the results of SVM, DNN and EN also revealed many different interesting drug candidates with repurposing potential. For example, for depression and anxiety disorders, DNN and EN both identified several histone deacetylase (HDAC) inhibitors (such as trichostatin A, vorinostat and scriptaid) as top repositioning hits. HDAC have been implicated in the pathogenesis of psychiatric disorders including depression, as reviewed by Fuchikami et al. 50 . HDAC inhibitors have been reported to produce antidepressant-like effects in animal models 51, 52 . The EN algorithm also identified metformin as one of the top repositioning hits. A study in Taiwan reported that the risk of depression in diabetic patients was reduced by ~60% for those given metformin with sulfonylurea 53 . Another study reported improved depressive symptoms in cognitive function for depressed patients with diabetes 54 . Tetrandrine, a calcium channel blocker on the list, demonstrated antidepressant-like effects in a rodent model 55 . As for schizophrenia, it is noteworthy that EN reveals spiperone, an antipsychotic not listed in ATC or MEDI-HPS, as the top repositioning hit. Another top hit ranked by the deep learning algorithm, pizotifen, is a 5-HT 2A / 2C antagonist. This action is shared by many atypical antipsychotics such as clozapine and olanzapine 56 . The selective estrogen receptor modulator raloxifene was also ranked among the top and it was shown to improve schizophrenia symptom scores in double-blind RCTs of post-menopausal women 57, 58 .
Top 100 repositioning hits using SVM, DNN and EN for schizophrenia in addition to depression and anxiety disorders are given in Supplementary Tables 1-3 .
Discussions
In this study we presented a repositioning framework by predicting drug indications based on expression profiles. We employed and compared five state-of-the-art machine learning methods to perform predictions, and SVM achieved the best predictive performance overall. We also observed that the top repositioning hits are enriched for psychiatric drugs considered for clinical trials and that many repositioning hits are backed up by evidence form animal or clinical studies, supporting the validity of our approach.
Concerning the performance of different machine learning classifiers, we have employed five methods in total, and all but one (EN) are non-linear classifiers. SVM is a kernel-based learning approach that is widely used in bioinformatics. On the other hand, deep learning methods (such as DNN) that are based on the principles of representation learning 59 have witnessed rapid advances in the last decade, especially in the field of computer vision. While potentially powerful, current successful applications typically require very large datasets for training, and we suspect that the relatively modest sample size (N = 3478) of our dataset may have limited DNN to achieve the optimal predictive ability. We have used at most three layers in view of the moderate sample size, and the complexity of the network may be increased with larger samples. Nevertheless, this study shows that deep learning can achieve reasonable performance in repurposing drugs for a disease, and the approach is worthy of further explorations. While logistic regression with EN is a linear classifier, it performed well overall though lagging behind SVM. However, in our case SVM apparently strikes the best balance between model complexity and stability. It is not entirely clear why the tree-based methods did not perform as well as the other approaches. A possible explanation is that the number of features is large while the number of signals is likely small; the classification accuracy with a limited number of randomly selected features in each tree may be too low for an overall satisfactory performance. Notwithstanding the differences in predictive performances, different algorithms are based on diverse model assumptions and principles, and as shown above, methods with slightly lower predictive accuracy still reveal useful repositioning candidates that are of different mechanisms of actions.
To the best of our knowledge, this is the first study to employ a comprehensive array of machine learning methods on drug expression profiles for the repurposing of particular diseases; it is also the first application in psychopharmacology. In a related work, Aliper et al. made use of the drug transcriptome to predict drug classes e.g. drugs for neurological diseases, drugs for cardiovascular diseases, anti-cancer agents etc. 60 . Here our focus is different and perhaps clinically more relevant in that we directly identify repositioning opportunities for a particular disorder. In addition, we concentrated on the study of psychiatric disorders, which was not explicitly considered in Aliper et al. 60 . Interestingly, deep neural network was reported to be the best performing method in their study. However their study 60 and the present work are not directly comparable as the outcomes studied are different and the evaluation metrics also differ. F1 score was used in Aliper et al. 60 (although the choice of a cut-off probability for classification was not explicitly stated) while we used ROC-AUC, PR-AUC and log loss as performance indicators.
Here we aim to provide a proof-of-concept example showing that the application of machine learning methodologies on drug expression profiles may help to identify candidates for repositioning, particularly for psychiatric disorders. Nevertheless, given the variety of methods and rapid advances in machine learning and computational drug repurposing, there is still plenty of room for improvement. Firstly, we only consider drug indications and the drug-induced transcriptomic changes in our prediction model. This makes the method very flexible and widely applicable to any compounds or drugs for which an expression profile is available. The use of drug transcriptome evades the need of specifying targets and knowing the mechanisms of actions. However, it is possible that our methods may be further improved by incorporating other information such as drug targets and chemical structure, if such information is available. As for the prediction algorithm, in our dataset the number of positive labels is small and prediction accuracy may be improved by modifications that take into account this imbalance 61 . We will leave this work in a further study. We covered five more commonly used algorithms here but this coverage is not complete; further studies may benefit from the use of more advanced or recently developed learning methods. We also notice that there is an ongoing effort to expand the coverage of CMap 62 , and that a preprint article with updated full data and documentations have just been released. We are planning to further explore the current framework in the expanded dataset.
It is reassuring to observe that many repositioning hits are supported by previous studies and the results enriched for psychiatric drugs considered in clinical trials. However, we stress that further well-designed pre-clinical and clinical studies are necessary before the any results can be brought into clinical practice.
We believe that this study will open a new avenue for computational drug repositioning, and will stimulate further research to bridge the gap between machine learning and biomedical applications especially drug development. The list of repositioning candidates will also serve as a useful resource for researchers and clinicians working on schizophrenia as well as depression and anxiety disorders, which are illnesses very much in need of new therapies. The learning algorithm with the best performance in each dataset (for each predictive performance measure) is marked in bold. 
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